Industry P pharmaphorum
On GDF-15 neutralisation and cachexia, with CatalYm
On GDF-15 neutralisation and cachexia, with CatalYm Nicole.Raleigh Sat, 24/10/2026 - 15:51
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry P pharmaphorum
On GDF-15 neutralisation and cachexia, with CatalYm Nicole.Raleigh Sat, 24/10/2026 - 15:51
Agriculture
CropLife
Congressman Sorensen tours West Central FS, highlighting agricultural innovation, farmer needs, and the importance of industry-policy collaboration. The post Congressman Eric Sorensen Visits West Central FS to Discuss Illinois Agriculture and Farmer Needs appeared first on CropLi…
Software P Paired Ends
A limited demonstration that AI reviews can do the job of human reviewers at improving papers. Deciding what to publish still needs an accountable editor with human reviewers they trust.
Clinical
Inside Precision Medicine
A Phase III trial involving 1,137 patients found that a personalized mRNA vaccine combined with pembrolizumab significantly reduced melanoma recurrence and distant metastasis following surgery. The post Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phas…
Industry P pharmaphorum
ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer Phil.Taylor Sat, 24/10/2026 - 14:13
Software M Mac in Chem
Burette is a macOS desktop app and Quick Look extension for molecular previews: Mol* 3D, xyzrender SVG, and RDKit grids. There is a review of
Industry P pharmaphorum
ESMO26: Halda buy delivers a win for J&J in prostate cancer Phil.Taylor Sat, 24/10/2026 - 13:08
Industry P pharmaphorum
ESMO26: BMS dual-acting ADC beats chemo in breast cancer Phil.Taylor Sat, 24/10/2026 - 12:08
Industry P pharmaphorum
ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer Phil.Taylor Sat, 24/10/2026 - 10:55
Industry P pharmaphorum
ESMO26: Neoadjuvant Enhertu fails in early breast cancer Phil.Taylor Sat, 24/10/2026 - 09:01
Software T The Niche
I just wrote about the complicated MUSE cell situation in the US. Marketing of these unapproved cells is all over the place now. It’s so widespread that celebrities and other well-known folks are trying MUSE cells. Trump’s granddaughter’s MUSE cell procedure For instance, now we…
Industry
BioCentury
BIOCENTURY | FINANCEAFTER LYCIA’S AFTERMARKET SURGE, MORE BIOTECHS LOOK TO NASDAQ: FINANCE REPORTRezera, TriGemX, Prana aim to list via different methods; fundings for Disc, Arcus, Zai, Pathos, Estuary, Nouscom and more
Industry
BioCentury
BIOCENTURY | DEALSLIMITED COMPETITION BEHIND ICOTYDE MAY HELP JUSTIFY GILEAD’S $1.3B PEPSTAR DEALSan Francisco Bay Area biotech acquires oral IL-23R program from under-the-radar Chinese company, with IBD combinations offering additional opportunity
Clinical N Nature Medicine
Clinical N Nature Medicine
Industry S SecureBio
Google's new Gemini is the second-highest scoring model on our biological capability evaluations and has stronger refusal safeguards than previous Gemini models.
Regulatory B BioPharm International
The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.
Regulatory P Pharmaceutical Executive
FDA approved an at-home induction option for risankizumab-rzaa in adults with moderate-to-severe Crohn's disease, based on the phase 3 AFFIRM trial.
Industry P Pharmaceutical Executive
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an…
Funding B BioPharm International
Gilead agrees to acquire PepStar’s oral IL-23R peptide program for $1.275 billion, Zymeworks licenses its DLL3-targeted trispecific T-cell engager ZW209 to Roche, and the US Treasury proposes adding biotechnology to its outbound investment restrictions.
Industry
STAT Biotech
In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
Clinical
STAT Biotech
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
Software
MedTech Dive
Provider groups are lobbying the Food and Drug Administration to make tech companies responsible for the safety and performance of generative AI-backed medical devices, arguing the tools’ makers are best equipped to evaluate them.
Software M Mac in Chem
Avogadro is an advanced open source molecular editor and visualization tool. Download and installation instructions are here https://avogadro.cc/install/index.html
Industry
MedCity News
Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could compete against Johnson & Johnson’s Icotyde, an oral peptide that blocks the same target and is a…
Manufacturing P Pharmaceutical Executive
Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
Manufacturing B BioProcess International
The proposed trial briefly resurfaced with an updated protocol and ethical approval from the University of Southern Denmark, but Bissau-Guinean authorities firmly denied it would take place.
Industry
Inside Precision Medicine
An experimental bispecific antibody that selectively activates tumor-associated T cells has produced early responses in advanced cancers, including those resistant to checkpoint inhibitors. The post Bispecific Immunotherapy Shows Early Activity in Treatment-Resistant Solid Tumors…
Clinical
STAT Biotech
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
Industry
Clinical Trials Arena
A study published in October 2026 suggests that a specific type of depression correlates with a person’s body clock patterns. The post New evidence shows depression linked to circadian rhythm appeared first on Clinical Trials Arena.
Industry B BioPharm International
FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.
Industry P pharmaphorum
ESMO26: Lowering toxicity, extending lives, with Syncromune Nicole.Raleigh Fri, 23/10/2026 - 16:00
Software B BioPharm International
Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
Research P pharmaphorum
Why precision biomarkers will change the future of breast cancer care Nicole.Raleigh Fri, 23/10/2026 - 15:48
Industry B BioPharm International
Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.
Regulatory
MHRA
As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.
Regulatory A Applied Clinical Trials
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Industry
BioPharma Dive
The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.
Industry P pharmaphorum
Ending rational disengagement: Bridging the strategy-reality gap Nicole.Raleigh Fri, 23/10/2026 - 15:30
Industry
STAT Biotech
As the ESMO conference kicks off, Tango's pancreatic cancer combination shows striking promise and detailed data on Moderna and Merck's cancer vaccine is released early.